Flossbach Von Storch AG Reduces Stock Position in Stryker Co. (NYSE:SYK)

Flossbach Von Storch AG cut its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 1.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 508,225 shares of the medical technology company's stock after selling 6,629 shares during the period. Stryker comprises approximately 0.7% of Flossbach Von Storch AG's holdings, making the stock its 28th largest position. Flossbach Von Storch AG owned approximately 0.13% of Stryker worth $152,193,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Bremer Bank National Association raised its position in Stryker by 4.0% in the fourth quarter. Bremer Bank National Association now owns 888 shares of the medical technology company's stock worth $266,000 after acquiring an additional 34 shares during the period. Simon Quick Advisors LLC lifted its position in Stryker by 3.0% during the fourth quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company's stock valued at $347,000 after purchasing an additional 34 shares in the last quarter. Consolidated Portfolio Review Corp grew its holdings in Stryker by 3.6% during the fourth quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company's stock valued at $294,000 after purchasing an additional 34 shares during the period. MBL Wealth LLC grew its holdings in Stryker by 4.6% during the fourth quarter. MBL Wealth LLC now owns 850 shares of the medical technology company's stock valued at $255,000 after purchasing an additional 37 shares during the period. Finally, PDS Planning Inc increased its position in Stryker by 3.0% in the third quarter. PDS Planning Inc now owns 1,318 shares of the medical technology company's stock worth $360,000 after buying an additional 38 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Price Performance

NYSE SYK traded down $1.63 during mid-day trading on Wednesday, hitting $336.03. The stock had a trading volume of 1,056,153 shares, compared to its average volume of 1,252,351. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $361.41. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. The firm's 50 day moving average is $350.57 and its 200 day moving average is $312.03. The stock has a market capitalization of $127.85 billion, a price-to-earnings ratio of 40.73, a PEG ratio of 2.73 and a beta of 0.89.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.27 by $0.19. The firm had revenue of $5.82 billion during the quarter, compared to analysts' expectations of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. Stryker's revenue was up 11.8% compared to the same quarter last year. During the same period last year, the business earned $3.00 earnings per share. Equities research analysts forecast that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a dividend of $0.80 per share. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 annualized dividend and a yield of 0.95%. Stryker's dividend payout ratio (DPR) is 38.79%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on SYK. TD Cowen raised their target price on shares of Stryker from $365.00 to $400.00 and gave the stock a "buy" rating in a research note on Thursday, April 11th. Royal Bank of Canada raised their price target on Stryker from $360.00 to $386.00 and gave the company an "outperform" rating in a report on Monday. Canaccord Genuity Group raised Stryker from a "hold" rating to a "buy" rating and upped their price objective for the stock from $315.00 to $360.00 in a research note on Wednesday, January 31st. Evercore ISI lifted their target price on Stryker from $340.00 to $370.00 and gave the company an "outperform" rating in a research note on Thursday, April 4th. Finally, StockNews.com raised shares of Stryker from a "hold" rating to a "buy" rating in a report on Tuesday, January 23rd. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $339.22.

Insider Buying and Selling at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the company's stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the transaction, the chief accounting officer now owns 3,675 shares of the company's stock, valued at $1,317,414. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Ronda E. Stryker sold 201,146 shares of the stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the transaction, the director now owns 3,755,128 shares of the company's stock, valued at approximately $1,287,633,391.20. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now directly owns 3,675 shares of the company's stock, valued at $1,317,414. The disclosure for this sale can be found here. Insiders have sold 212,109 shares of company stock worth $72,845,768 over the last quarter. 5.50% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.